Related Experiment Video
Updated: Feb 5, 2026
06:46
Author Spotlight: Understanding the Effect of Herbal-Cake-Separated Moxibustion in Rats with Renal Faliure
Published on: December 22, 2023
1.2K
Calcific cardiomyopathy in advanced renal failure
Archives of Internal Medicine
|April 1, 1975
Summary
High calcium-phosphorus levels in uremic patients undergoing hemodialysis can lead to fatal heart complications. This study highlights the critical role of oral phosphate binders in preventing metastatic calcification.
Area of Science:
- Nephrology
- Cardiology
- Pathology
Background:
- Uremic patients on maintenance hemodialysis often face complications related to mineral and bone disorders.
- Elevated calcium-phosphate product is a known risk factor for calcification in chronic kidney disease.
Purpose of the Study:
- To investigate the link between high calcium-phosphorus product and fatal cardiac complications in hemodialysis patients.
- To identify the role of metastatic myocardial calcification in intractable heart failure and atrioventricular block.
Main Methods:
- Case study analysis of four uremic patients on maintenance hemodialysis.
- Review of clinical data including heart failure, atrioventricular block, and calcium-phosphorus product levels.
- Autopsy findings to confirm metastatic myocardial calcification.
Main Results:
- All four patients presented with intractable heart failure and atrioventricular block.
- Persistently high calcium-phosphorus products (over 60) were observed in all cases.
- Autopsy confirmed metastatic myocardial calcification as a common pathological finding.
Conclusions:
- Inability to effectively manage phosphate levels with oral phosphate binders can lead to fatal metastatic myocardial calcification.
- Maintaining a low calcium-phosphorus product is crucial for preventing severe cardiac complications in hemodialysis patients.
- This highlights a critical treatment challenge and a potentially fatal complication in uremic patients.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
494
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
494
01:29Cardiomyopathy V: Interprofessional Care
455
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
455
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
545
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
545
01:30Cardiomyopathy II: Dilated Cardiomyopathy
573
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
573
01:25Cardiomyopathy I: Introduction and Classification
611
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
611
01:11Renal Failure: Dose Adjustments
480
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
480